Yahoo Finance·2025-10-17 23:00Core Insights - NextEra Energy has received a 20-year license renewal for its Point Beach Nuclear Plant, allowing operations through 2050 and 2053, which supports its energy initiatives [1] - NextEra Energy is a leading electric utility holding company focused on scaling electricity and expanding resources to meet increasing U.S. energy demand [2] - The company reported a 10.4% year-over-year sales increase to $6.7 billion and a 25% rise in net income to $2.03 billion in its most recent quarter [6] Financial Performance - NextEra's stock is trading at $85.05 with a forward annual dividend of $2.27, yielding approximately 2.7% and a dividend payout ratio of 59.95% [6] - Lowe's Companies reported a 1.6% year-over-year sales increase to $23.96 billion and a net income rise of 0.6% to $2.4 billion, with stock trading at $243.10 and a forward annual dividend of $4.80, yielding just under 2% [10] - Atmos Energy reported a 19.6% sales increase to $838.8 million and a net income rise of 12.6% to $186.4 million, with stock trading at $176.37 and a forward annual dividend of $3.48, yielding approximately 2% [14] - Abbott Laboratories saw a 7.4% sales increase to $11.14 billion and a 36.6% rise in net income to $1.78 billion, with stock trading at $127.63 and a forward annual dividend of $2.36, yielding approximately 1.8% [19] - Linde Plc reported a 2.8% sales increase to $8.5 billion and a 6.2% rise in net income to $1.77 billion, with stock trading at $444.24 and a forward annual dividend of $6.00, yielding approximately 1.4% [23] Analyst Ratings - NextEra Energy has a consensus rating of "Moderate Buy" with a score of 4.05/5 from 21 analysts, reflecting increased sentiment over the last three months [7] - Lowe's Companies has a consensus rating of "Moderate Buy" with a score of 4.21/5 from 29 analysts, showing a slight decrease in sentiment [11] - Atmos Energy has a consensus rating of "Moderate Buy" with a score of 3.64/5 from 14 analysts, with consistent but slightly declining sentiment [15] - Abbott Laboratories has a consensus rating of "Strong Buy" with a score of 4.45/5 from 29 analysts, strengthening from a "Moderate Buy" three months ago [20] - Linde Plc has a consensus rating of "Strong Buy" with a score of 4.41/5 from 27 analysts, with no analysts holding a "sell" rating [24]